Ticker Details
ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia.
IPO Date:	June 1, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.85B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.44 | 2.65%
Avg Daily Range (30 D):	$0.42 | 1.92%
Avg Daily Range (90 D):	$0.43 | 1.76%

Institutional Daily Volume
Avg Daily Volume:	1.22M
Avg Daily Volume (30 D):	1.5M
Avg Daily Volume (90 D):	1.21M

Trade Size
Avg Trade Size (Sh.):	127
Avg Trade Size (Sh.) (30 D):	61
Avg Trade Size (Sh.) (90 D):	59

Institutional Trades
Total Institutional Trades:	10,268
Avg Institutional Trade:	$2.33M
Avg Institutional Trade (30 D):	$4.24M
Avg Institutional Trade (90 D):	$3.74M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$4.27M
Avg Closing Trade (30 D):	$7.27M
Avg Closing Trade (90 D):	$7.14M
Avg Closing Volume:	177.57K

News

Dec 4, 2025 @ 12:12 AM Acadia Stock Up 59% in a Year — Is a $51 Mi... Source: Jonathan Ponciano

Sep 11, 2025 @ 3:30 AM Questex’s Fierce Pharma Announces the 2025 ... Source: Linda Lam

Apr 22, 2025 @ 5:00 PM Parkinson’s Disease Therapeutic Domain Proj... Source: Delveinsight

Feb 11, 2025 @ 8:48 AM Neuroregeneration Therapy Market to Surpass USD 64... Source: Transparency Market Research

Jun 27, 2024 @ 12:41 PM This Vertex Pharmaceuticals Analyst Begins Coverag... Source: Avi Kapoor

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$2.32	$1.62	$2.32
Diluted EPS	$2.3	$1.61	$2.3
Revenue	$1.07B	$283.99M	$1.07B
Gross Profit	$982.51M	$257.76M	$982.51M
Net Income / Loss	$391M	$273.57M	$391M
Operating Income / Loss	$104.81M	$17.39M	$104.81M
Cost of Revenue	$89M	$26.23M	$89M
Net Cash Flow	$-142.85M	$-81.93M	$-142.85M
PE Ratio	9.45